semaj83/ctmatch_classification huggingface dataset:
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 55.0-95.0,  Dementia, Alzheimer Type Non-institutionalized patients with a diagnosis of Alzheimer's disease as defined by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) with symptoms of delusions or hallucinations, which have been present, at least intermittently for one month or longer Mini Mental State Examination (MMSE) score of 6 to 24 points Patients capable of self locomotion or locomotion with the aid of an assistive device Patients with an identified caregiver or proxy For Extension Phase Eligible patients were males and females who had completed the 10-week Acute Phase in either treatment group; had a Week 10 Total Score of ≥ 6 on the NPI; and were, in the judgment of the investigator, deemed suitable for participation in the long-term trial Treatment beyond 140 weeks All subjects who completed the extension phase of CN138-006 in any French Investigational Site may be considered eligible for entry until they are no longer receiving clinical benefit, per the investigator's judgment  Patients with an Axis I (DSM IV) diagnosis of delirium amnestic disorders bipolar disorder schizophrenia or schizoaffective disorder mood disorder with psychotic features Patients with reversible causes of dementia Patients with psychotic symptoms continuously present since prior to the onset of the symptoms of dementia Patients with psychotic symptoms that are better accounted for by another general medical condition or by direct physiological effects of a substance Patients with a current major depressive episode with psychotic symptoms of hallucinations or delusions
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Graft Versus Host Disease (GVHD) Acute Myocardial Infarction (AMI) Age 18 to 35 years Willingness to provide written informed consent  Presence of risk factors for or clinical evidence of Human immunodeficiency virus (type 1 and 2), Hepatitis B, Hepatitis C, Human T-lymphotrophic virus (type I and II), Human transmissible spongiform encephalopathy (including Creutzfeldt-Jakob disease) treponema pallidum Presence of communicable disease risk associated with xenotransplantation Test positive for Human immunodeficiency virus (type 1 and 2), Hepatitis B, Hepatitis C, Human T-lymphotrophic virus (type I and II), cytomegalovirus (CVM), West Nile Virus, treponema pallidum Use of investigational drug within 30 days or 5 half lives which ever is longer. Use of investigational implanted device History of malignancy Pregnancy In the opinion of the hematologist or the investigator, a condition that compromises the ability of the donor to safely provide BM donation
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Menopause Postmenopausal Vaginal Atrophy Atrophic vaginitis due to estrogen deficiency Post-menopausal
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 40.0-85.0,  Parkinson's Disease Mild Cognitive Impairment Participants must be experiencing symptoms of mild cognitive impairment; this will be determined by study personnel Participants must be on a sable medication regimen for 2 months prior to starting the study (necessary dose adjustments during the study are acceptable) Participants are capable of giving informed consent supported by not meeting Parkinson's disease Dementia criteria; this will be determined by study personnel  Active suicide ideation Weighing less than 100 lbs (45 kgs) History of Deep Brain Stimulation surgery Diagnosis of Dementia Taking certain types of medications may be an  this will be reviewed with all potential participants Females that are pregnant, planning to become pregnant, or are breastfeeding will not be included in the study. Females of childbearing potential will need to verify that they are not pregnant by a negative urine pregnancy test
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Alzheimer's Disease for AD cases Diagnosis of probable AD, defined according to the criteria51 Light to moderate severity of the disease, defined by a MMSE score >10 (global evaluation of cognition) Patient aged 50 years or more Patient benefiting from social insurance for controls Absence of suspicion of dementia, based on normal performance according to age and educational level at neuropsychological testing defined as Free recall ≥17 and total recall ≥40 for the Free and Cued Selective Reminding Test (Grober and Buschke test 52) MMSE ≥ norm for age and educational level (defined by mean SD) Isaac's set test ≥ norm for age and educational level (defined by mean  for all patients  History of Parkinson's disease or other neurodegenerative disorder History of Horton's disease History of inflammatory neuropathies (in particular Devic's disease, multiple sclerosis) History of vascular ischemic neuropathies and chronic intracranial hypertension History of pituitary tumors Presence of diseases (systemic and/or ocular diseases) or behavioural or cognitive symptoms incompatible with eye examination Known diabetes Person under tutorship or curatorship, person unable to express consent Additional
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Differentiated Thyroid Cancer Age over 18 years Patient has thyroid cancer Patient is judged as being capable of understanding the information sheet and of giving informed consent (Mental Capacity Act 2005) Responsible clinician is approached and is happy for the patient to be included in the study  Age of less than 18 years Patient has additional risk infections (HIV, Hep B/C) Patient is involved in other medicinal or treatment based clinical trial at the time of recruitment or in the previous 4 months
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer newly diagnosed breast cancer no metastasis detected operation for breast cancer female patient unilateral breast cancer informed consent given age min. 18 yrs  metastasis of breast cancer bilateral breast cancer other cancer within the last 5yrs
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Multiple Sclerosis, Relapsing-remitting Enrolled into the 2-year, double-blind, placebo-controlled ASA study and entered 3 year extension study MRI was performed on all patients using a 1.5 T magnet  MRI images unable to be processed All 5 MRI time points not collected
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Arthrosis of the Knee The participants of the study are patients that have been scheduled for a primary TKA using the usual indications for TKA at the Department of Planned Elective Surgery Z, Gentofte Hospital Severe osteoarthrosis of the knee with indication for a TKA Age between 40 and 70 years  Diseases affecting the bone metabolism (osteoporosis, Pagets disease, hyperparathyreoidism etc.) Patients estimated not to be able to understand the "Information to patients" papers or do not want to participate in the study
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Knee Arthritis patients waiting for knee replacement  neurologic disease
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 8.0-21.0,  Brain Structural Connectivity Cognitive Function Ages 8-21 without current and past history of any psychiatric disorder and autistic symptoms  Current symptoms or lifetime history of DSM-IV-TR diagnosis of attention-deficit/hyperactivity disorder, pervasive developmental disorder, schizophrenia, schizoaffective disorder, delusional disorder, other psychotic disorder, organic psychosis, bipolar disorder, depression, severe anxiety disorders or substance use With neurodegenerative disorder, epilepsy, involuntary movement disorder, congenital metabolic disorder, brain tumor, history of severe head trauma, and history of craniotomy With major systemic disease Full-scale IQ < 80
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 65.0-89.0,  Mild Cognitive Impairment Dementia Memory Disorders Age between 65 and 89 Successful completion of primary school MCI, as Mini Mental State Examination score between 20 and 27 and confirmation through neuropsychological examination by a specialist, according to current guidelines  Moderate/severe dementia Clinical signs of depressive disorder or other primary psychiatric disorders Neoplastic diseases Neurologic or musculoskeletal deficits barring neuropsychological examination or physical or cognitive training Severe heart disease End stage renal disease (eGFR<35 ml/min(1.73 m2) Severe chronic obstructive pulmonary disease (COPD) and/or respiratory failure Complicated or decompensated diabetes Overt peripheral artery disease Any inability to successfully complete a brain magnetic resonance scan
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Ischemic Stroke Involving Corticospinal Tract. Patients of 18 to 90 years old Subcortical stroke Achievement of the internal capsule, according to MRI Ability to perform MRI within 10 days after the onset of symptoms NIHSS over or equal 2 and < 20 Rankin Score over or equal 1 and ≤ 5 Written informed consent after information about the protocol, from patients or reliable person if patient is in incapacity to sign Affiliation to a social security scheme  Pregnant or nursing women Other cerebral lesion, concomitant or preexisting Concomitant disease causing unfavorable prognosis within 3 months after pre-existing psychiatric illness Alcoholism or other chronic intoxication Cortical localization of the infarction Patient in a coma, who cannot be examined and evaluated Patient intubated, ventilated, sedated Cerebral hemorrhage, intra-parenchymal and / or subarachnoid Persons protected by law (guardianship, curators and judicial protection)
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 40.0-79.0,  Lower Limb Spasticity After Stroke patients with lower limb spasticity after stroke duration more than 6 months Modified Ashworth Scale of ankle joint more than 2  patients with previous botulinum toxin injections to lower limbs patients with serious hepatic, renal or cardiac dysfunction patients with respiratory failure patients who cannot understand the instructions
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Neoplasms Newly diagnosis of breast cancer for which surgical intervention is planned  patients received neoadjuvant chemotherapy before breast surgery
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Atrial Fibrillation Heart Failure Stroke Myocardial Infarction Patients with a coded diagnosis for atrial fibrillation in their primary or secondary care record Patients in GPRD practices which are deemed "up to standard" by GPRD Patients whose records are deemed "acceptable" by GPRD and contain at least one year of data Patients whose age and sex, as recorded in GPRD is the same as that recorded in HES  A diagnosis of heart failure, stroke, or myocardial infarction occurring before diagnosis of atrial fibrillation
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 65.0-85.0,  Disturbance; Balance, Labyrinth Parkinson´s Disease Elderly The patient is able to provide informed consent Definitive Idiopathic Parkinson's Disease as diagnosed by a Neurologist Hoehn and Yahr Stage 1-3 Able to ambulate without an assistive device On stable doses of Parkinson's medications prior to study onset  Mini Mental Status Exam (MMSE) < 24 Change in Parkinson's medications in the duration of study Uncontrolled orthostasis Symptomatic coronary artery disease Fracture of lower limb prior to study onset Other neurologic diagnosis Physical therapy before and during to study duration Significant camptocormia Any medical condition which the physician investigator determines would compromise the safety of exercise program for the subject
Patient description: A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Sleep Disordered Breathing Alzheimer's Disease Male and female subjects with normal cognition and >50 years of age will be enrolled. Younger subjects are not included as the risk for cognitive impairment is too low. Moreover, by selecting this age-range we minimize the possibility of including early-onset genetic forms of neurodegenerative diseases such as Alzheimer's disease and Frontotemporal Dementia Normal subjects will be within normal limits on neurological and psychiatric examinations. All subjects enrolled will have both a Clinical Dementia Rating = 0 and Global Deterioration Scale < 3 All subjects will have had a minimum of 12 years education.The education restriction reduces performance variance on cognitive test measures and improves the sensitivity for detecting pathology and disease progression using the robust norms available at NYU School of Medicine All subjects will have an informed family member or life partner interviewed to confirm the reliability of the subject interview. All subjects will agree to the MRI imaging, the lumbar puncture, apolipoprotein E (ApoE) genotyping and DNA banking  Diagnosis of any brain disease or MRI evidence of brain damage including significant trauma, hydrocephalus, seizures, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders). Persons with silent cortical infarcts are excluded. Subcortical infarcts and white matter lesions are not exclusions History of brain tumor Any radiation or chemotherapy anywhere in the body in the past 3-years Significant history of alcoholism or drug abuse History of psychiatric illness (e.g., schizophrenia, mania, PTSD, or life long history of major depression) Hamilton Depression Scale >16 only with history of life long depressive episodes. Otherwise not excluded Evidence of clinically relevant and uncontrolled cardiac, pulmonary, or hypothyroid or hematological conditions. Insulin dependent diabetes and/or history or treated hypertension are not an exclusion. Normal subjects with current levels of HbA1c >5.9% or diabetics >7.0% (American Diabetes Association, 2010) and/or current blood pressure levels >140/90 mm Hg (JNC on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, 2003) will be advised to seek referral Physical impairment of such severity as to adversely affect the validity of psychological testing Hostility or refusal to cooperate Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging